Loading...
XTSEEDT
Market cap106mUSD
Jan 08, Last price  
0.54CAD
1D
-5.26%
1Q
-5.26%
Jan 2017
96.36%
Name

Spectral Medical Inc

Chart & Performance

D1W1MN
XTSE:EDT chart
P/E
—
P/S
96.07
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.82%
Rev. gr., 5y
-16.08%
Revenues
2m
-4.14%
10,001,0007,272,0002,169,0002,993,0003,011,0003,283,0002,821,0002,539,0002,589,0002,672,0002,964,0003,089,0003,545,0003,806,0003,840,0002,868,0002,101,0002,052,0001,667,0001,598,000
Net income
-16m
L+38.61%
-7,358,000-4,655,0003,730,000-1,666,000-1,502,000-2,764,000-6,567,000-6,713,000-8,543,000-11,307,000-9,492,000-9,524,000-10,149,000-3,939,000-2,489,000-4,868,000-8,982,000-8,720,000-11,299,000-15,662,000
CFO
-11m
L+7.99%
-5,059,000-4,209,000-1,270,000-732,000-523,000-1,108,000-4,477,000-6,273,000-7,725,000-9,191,000-10,008,000-9,136,000-11,125,000-3,595,000-2,322,000-2,738,000-324,000-8,701,000-9,928,000-10,721,000
Dividend
Dec 19, 20110.12 CAD/sh
Earnings
Mar 26, 2025

Profile

Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
URL
https://spectraldx.com/
IPO date
Jul 16, 1992
Employees
32
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,598
-4.14%
1,667
-18.76%
Cost of revenue
7,546
11,792
Unusual Expense (Income)
NOPBT
(5,948)
(10,125)
NOPBT Margin
Operating Taxes
1,706
Tax Rate
NOPAT
(5,948)
(11,831)
Net income
(15,662)
38.61%
(11,299)
29.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,025
BB yield
-4.03%
Debt
Debt current
385
96
Long-term debt
8,797
7,065
Deferred revenue
3,342
4,011
Other long-term liabilities
(6,129)
Net debt
6,230
(2,251)
Cash flow
Cash from operating activities
(10,721)
(9,928)
CAPEX
(185)
(33)
Cash from investing activities
(185)
(33)
Cash from financing activities
5,444
9,485
FCF
(408)
(11,468)
Balance
Cash
2,952
8,414
Long term investments
998
Excess cash
2,872
9,329
Stockholders' equity
(25,465)
(11,296)
Invested Capital
20,819
13,300
ROIC
ROCE
128.02%
EV
Common stock shares outstanding
278,563
269,843
Price
0.43
14.86%
0.37
68.18%
Market cap
118,389
18.58%
99,842
79.76%
EV
124,619
97,591
EBITDA
(5,730)
(9,853)
EV/EBITDA
Interest
1,334
104
Interest/NOPBT